ES2829199T3 - Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas - Google Patents
Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas Download PDFInfo
- Publication number
- ES2829199T3 ES2829199T3 ES18181451T ES18181451T ES2829199T3 ES 2829199 T3 ES2829199 T3 ES 2829199T3 ES 18181451 T ES18181451 T ES 18181451T ES 18181451 T ES18181451 T ES 18181451T ES 2829199 T3 ES2829199 T3 ES 2829199T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- bip
- sequence
- expression
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41592610P | 2010-11-22 | 2010-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2829199T3 true ES2829199T3 (es) | 2021-05-31 |
Family
ID=46146394
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18181451T Active ES2829199T3 (es) | 2010-11-22 | 2011-11-22 | Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas |
| ES11843849.8T Active ES2687415T3 (es) | 2010-11-22 | 2011-11-22 | Nuevas secuencias señal para mejorar las expresiones de proteínas y la secreción de enzimas recombinantes y de otras proteínas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11843849.8T Active ES2687415T3 (es) | 2010-11-22 | 2011-11-22 | Nuevas secuencias señal para mejorar las expresiones de proteínas y la secreción de enzimas recombinantes y de otras proteínas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9279007B2 (enExample) |
| EP (2) | EP3461905B1 (enExample) |
| JP (1) | JP2014503198A (enExample) |
| KR (2) | KR20190060888A (enExample) |
| CN (1) | CN103328649B (enExample) |
| BR (1) | BR112013012671B1 (enExample) |
| CA (1) | CA2818689C (enExample) |
| CY (1) | CY1121049T1 (enExample) |
| DK (2) | DK3461905T3 (enExample) |
| ES (2) | ES2829199T3 (enExample) |
| HR (1) | HRP20181315T1 (enExample) |
| HU (1) | HUE039070T2 (enExample) |
| LT (1) | LT2643468T (enExample) |
| PL (1) | PL2643468T3 (enExample) |
| PT (1) | PT2643468T (enExample) |
| RS (1) | RS57601B1 (enExample) |
| SI (1) | SI2643468T1 (enExample) |
| SM (1) | SMT201800466T1 (enExample) |
| WO (1) | WO2012071422A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20192243T1 (hr) * | 2014-07-03 | 2020-03-06 | F. Hoffmann - La Roche Ag | Polipeptidni ekspresijski sustavi |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| AU2018227583B2 (en) | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CN111936624A (zh) * | 2017-11-30 | 2020-11-13 | 阿米库斯治疗学公司 | Cdkl5表达变体和cdkl5融合蛋白 |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| TW202344691A (zh) | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| JP7577650B2 (ja) | 2018-10-10 | 2024-11-05 | アミカス セラピューティックス インコーポレイテッド | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| JP2022514863A (ja) * | 2018-12-19 | 2022-02-16 | ヴェルサメブ アーゲー | タンパク質をコードするｒｎａ |
| BR112021017744A2 (pt) | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| US20220193261A1 (en) * | 2019-04-30 | 2022-06-23 | The Trustees Of The University Of Pennsylvania | Compositions useful for treatment of pompe disease |
| CA3140668A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| WO2021087282A1 (en) * | 2019-10-30 | 2021-05-06 | Amicus Therapeutics, Inc. | Recombinant cdkl5 proteins, gene therapy and production methods |
| CN112342247B (zh) * | 2020-11-10 | 2022-03-11 | 江苏科技大学 | 一种提高家蚕细胞表达外源蛋白分泌率的方法 |
| WO2022119890A1 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| US20250034533A1 (en) | 2021-11-12 | 2025-01-30 | Amicus Therapeutics, Inc. | Compositions And Methods For Treating Mucopolysaccharidosis IIIA |
| WO2025264978A2 (en) | 2024-06-20 | 2025-12-26 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a proteins and gene therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000031113A1 (en) * | 1998-11-24 | 2000-06-02 | Bristol-Myers Squibb Company | INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| EP1689766B1 (en) * | 2003-11-06 | 2012-04-25 | Danisco US Inc. | Expression in filamentous fungi of protease inhibitors and variants thereof |
| ATE474917T1 (de) * | 2006-04-11 | 2010-08-15 | Csl Behring Gmbh | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
-
2011
- 2011-11-22 HR HRP20181315TT patent/HRP20181315T1/hr unknown
- 2011-11-22 EP EP18181451.8A patent/EP3461905B1/en active Active
- 2011-11-22 US US13/988,946 patent/US9279007B2/en active Active
- 2011-11-22 DK DK18181451.8T patent/DK3461905T3/da active
- 2011-11-22 DK DK11843849.8T patent/DK2643468T3/en active
- 2011-11-22 WO PCT/US2011/061862 patent/WO2012071422A2/en not_active Ceased
- 2011-11-22 EP EP11843849.8A patent/EP2643468B1/en active Active
- 2011-11-22 SI SI201131554T patent/SI2643468T1/sl unknown
- 2011-11-22 HU HUE11843849A patent/HUE039070T2/hu unknown
- 2011-11-22 ES ES18181451T patent/ES2829199T3/es active Active
- 2011-11-22 CA CA2818689A patent/CA2818689C/en active Active
- 2011-11-22 CN CN201180065369.5A patent/CN103328649B/zh active Active
- 2011-11-22 LT LTEP11843849.8T patent/LT2643468T/lt unknown
- 2011-11-22 KR KR1020197015057A patent/KR20190060888A/ko not_active Ceased
- 2011-11-22 ES ES11843849.8T patent/ES2687415T3/es active Active
- 2011-11-22 KR KR1020137016110A patent/KR101984318B1/ko active Active
- 2011-11-22 SM SM20180466T patent/SMT201800466T1/it unknown
- 2011-11-22 JP JP2013541026A patent/JP2014503198A/ja not_active Withdrawn
- 2011-11-22 PL PL11843849T patent/PL2643468T3/pl unknown
- 2011-11-22 BR BR112013012671-0A patent/BR112013012671B1/pt not_active IP Right Cessation
- 2011-11-22 RS RS20180986A patent/RS57601B1/sr unknown
- 2011-11-22 PT PT11843849T patent/PT2643468T/pt unknown
-
2018
- 2018-09-12 CY CY181100941T patent/CY1121049T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130121878A (ko) | 2013-11-06 |
| CN103328649A (zh) | 2013-09-25 |
| DK3461905T3 (da) | 2020-11-02 |
| CA2818689A1 (en) | 2012-05-31 |
| CN103328649B (zh) | 2016-06-22 |
| EP2643468B1 (en) | 2018-07-04 |
| EP3461905B1 (en) | 2020-08-05 |
| SMT201800466T1 (it) | 2018-11-09 |
| KR101984318B1 (ko) | 2019-05-31 |
| EP2643468A2 (en) | 2013-10-02 |
| LT2643468T (lt) | 2018-09-10 |
| US9279007B2 (en) | 2016-03-08 |
| RS57601B1 (sr) | 2018-11-30 |
| KR20190060888A (ko) | 2019-06-03 |
| ES2687415T3 (es) | 2018-10-25 |
| JP2014503198A (ja) | 2014-02-13 |
| EP3461905A1 (en) | 2019-04-03 |
| CY1121049T1 (el) | 2019-12-11 |
| WO2012071422A2 (en) | 2012-05-31 |
| BR112013012671A2 (pt) | 2016-10-11 |
| EP2643468A4 (en) | 2014-12-24 |
| US20140045216A1 (en) | 2014-02-13 |
| PT2643468T (pt) | 2018-10-11 |
| PL2643468T3 (pl) | 2018-11-30 |
| HRP20181315T1 (hr) | 2018-10-19 |
| SI2643468T1 (sl) | 2018-10-30 |
| HUE039070T2 (hu) | 2018-12-28 |
| WO2012071422A3 (en) | 2012-08-02 |
| CA2818689C (en) | 2021-09-21 |
| BR112013012671B1 (pt) | 2022-03-03 |
| DK2643468T3 (en) | 2018-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2687415T3 (es) | Nuevas secuencias señal para mejorar las expresiones de proteínas y la secreción de enzimas recombinantes y de otras proteínas | |
| US6207420B1 (en) | Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in Escherichia coli | |
| Johnson et al. | Post-translational processing of surfactant protein-C proprotein: targeting motifs in the NH2-terminal flanking domain are cleaved in late compartments | |
| KR20210032972A (ko) | 전사인자를 사용하여 단백질 발현을 증가시키는 수단 및 방법 | |
| CN117120618A (zh) | 用于增加蛋白质分泌的信号肽 | |
| CN102659928B (zh) | 一种人工合成的信号肽及其应用 | |
| Di Cola et al. | Large-scale translocation reversal within the thylakoid Tat system in vivo | |
| Bass et al. | Application of the E. coli trp promoter | |
| Salunkhe et al. | Strategies to maximize expression of rightly processed human interferon α2b in Pichia pastoris | |
| EP2630243A1 (en) | Secretion of recombinant polypeptides in the extracellular medium of diatoms | |
| CN103483423B (zh) | 一种人工合成的信号肽及其应用 | |
| CN101921315B (zh) | 一种人工合成的信号肽及其应用 | |
| Inagaki et al. | Protein translocation within chloroplast is similar in Euglena and higher plants | |
| US20210388046A1 (en) | Chimeric signal peptides for protein production | |
| HK40006980A (en) | Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins | |
| Eskridge et al. | The NH2 terminus of preproinsulin directs the translocation and glycosylation of a bacterial cytoplasmic protein by mammalian microsomal membranes. | |
| CN104059128B (zh) | 一种人工合成的信号肽及其应用 | |
| CN102659927B (zh) | 一种人工合成的信号肽及其应用 | |
| HK1189913B (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| HK1189913A (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| US20130059335A1 (en) | Use of a genetically modified cell line expressing functional asialoglycoprotein receptor in the production of sialylated glycoproteins | |
| Dede et al. | Recombinant production of hormonally active human insulin from pre-proinsulin by Tetrahymena thermophila | |
| Esposito et al. | Gateway cloning is compatible with protein secretion from Pichia pastoris | |
| JP2004337090A (ja) | セレノシステイン含有タンパク質産生遺伝子組換え動物 | |
| Lei Lei et al. | Prokaryotic expression of mouse Sox2 gene and preparation of its polyclonal antibody. |